Drug Profile
Squalamine - Enterin
Alternative Names: ENT-01; Enterin-01; kenterin; Squalamine phosphate - EnterinLatest Information Update: 14 Jul 2023
Price :
$50
*
At a glance
- Originator Enterin
- Class Antidementias; Antiparkinsonians; Antipsychotics; Nootropics; Small molecules
- Mechanism of Action Alpha-synuclein inhibitors; Angiogenesis inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Parkinson's disease
- Preclinical Multiple system atrophy; Psychotic disorders
- Research Autistic disorder
- No development reported Alzheimer's disease; Dementia; Schizophrenia
Most Recent Events
- 29 Jun 2023 Enterin terminates a phase IIb rollover trial in Parkinson's disease in USA (PO) (NCT04483479)
- 08 Jun 2023 Enterin suspends a phase-I clinical trial in Dementia (In adults, In the elderly) in USA (PO) (NCT03938922)
- 31 May 2023 Preclinical trials in Multiple system atrophy in USA (PO), prior to May 2023